Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout

Arthritis Care and Research

Volumn 62, Issue 9, 2010, Pages 1299-1305

  Perez Ruiz, Fernando ^a   Hernandez Baldizon, Samuel ^a   Herrero Beites, Ana M ^b   Gonzalez Gay, Miguel A ^c  

^a HOSPITAL DE CRUCES   (Spain)

^b Hospital de Gorliz   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; URIC ACID; CREATININE; URICOSURIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; GOUT; HUMAN; HYPERURICEMIA; KIDNEY COLIC; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; RISK FACTOR; URIC ACID URINE LEVEL; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL COLIC; TIME; URINE; UROLITHIASIS;

ALLOPURINOL; BENZBROMARONE; COHORT STUDIES; CREATININE; FOLLOW-UP STUDIES; GOUT; HUMANS; HYPERURICEMIA; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL COLIC; RISK FACTORS; TIME FACTORS; URIC ACID; URICOSURIC AGENTS; UROLITHIASIS;

EID: 77956401325     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20221     Document Type: Article

References (24)

1. Ogryzlo MA, Harrison J. Evaluation of uricosuric agents in chronic gout. Ann Rheum Dis 1957;16:425-37.
2. Thompson GR, Duff IF, Robinson WD, Mikkelsen WM, Galindez H. Long term uricosuric therapy in gout. Arthritis Rheum 1962;5:384-96.
3. Masbernard A, Giudicelli CP. Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J 1981;59:701-6.
4. Asplin JR. Uric acid stones. Sem Nephrol 1996;16:412-24.
5. Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 2004;13:181-9. (Pubitemid 38373140)
6. Simkin PA. When, why, and how should we quantify the excretion rate of uric acid? J Rheumatol 2001;28:1207-10.
7. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Tuneyoshhi KA, Fukuchi M, et al. A simple method of selecting gout patients for treatment with uricosuric agents, using spot urine and blood samples. J Rheumatol 2002;29:1937-41.
8. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
9. Perez-Ruiz F, Calabozo M, Garcia-Erauskin G, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002;47:610-3. (Pubitemid 35461313)
10. Bluestone R, Klinenberg J, Lee IK. Benzbromarone as a long-term uricosuric agent. Adv Exp Med Biol 1980;122A:283-6.
11. Niv Y, Fraser GM. The alkaline tide phenomenon. J Clin Gastroenterol 2002;35:5-8.
12. Finlayson B, Smith LH. Stability of first dissociable proton of uric acid. J Chem Engl Data 1974;19:94-7.
13. Pak CY, Poindexter JR, Peterson RD, Koska J, Sakhaee K. Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Urology 2002;60:789-94.
14. Coe FL, Evan A, Worcester E. Kidney stone disease [review]. J Clin Invest 2005;115:2598-608.
15. Kok DJ. Clinical implications of physicochemistry of stone formation. Endocrinol 2002;31:855-67.
16. Sorensen CM, Chandhoke PS. Hyperuricosuric calcium nephrolithiasis. Endocrinol Metab Clin N Am 2002;31:915-25.
17. Pak CY, Moe OW, Sakhaee K, Peterson RD, Poindexter JR. Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. J Urol 2005;173:1606-9.
18. Abate N, Chandalia M, Cabo-Chan AV, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386-92. (Pubitemid 38130632)
19. Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol 2007;2:883-8.
20. Sorensen LB, Levinson DJ. Clinical evaluation of benzbromarone: a new uricosuric drug. Arthritis Rheum 1976;19:183-90.
21. Simkin PA. New standards for uric acid excretion evidence for an inducible transporter [letter]. Arthritis Rheum 2003;49:735-6.
22. Singh H. Diagnosis and management of gout in the long-term care setting. Ann Long Term Care 2007;15:34-40. (Pubitemid 46911685)
23. Khatchdourian J, Preminger GM, Whitson PA, Adams-Huet B, Pak CY. Clinical and biochemical presentation of gout diathesis: comparison of uric acid versus pure calcium stone formation. J Urol 1995;154:1665-9.
24. Alvarez-Nemegyei J, Medina-Escobedo M, Villanueva-Jorge S, Vazquez-Mellado J. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? J Rheumatol 2005;32:2189-91.